clinical-trials
59 stories · Page 2 of 3
The Glioblastoma Trial No Drug Company Paid For Posted an 82% Six-Month Progression-Free Rate
Calgary oncologists bought controlled-release niacin at retail, added it to standard treatment, and cleared their own preset bar with room to spare. The trial is small, single-arm and untidy on paper, and it was paid for entirely with grant money.
CancerNature Medicine Retracted the Lung Cancer Trial That Made Infusion Timing Look Like a Free Win
Its protocol was dated January 2022 but cited papers from 2024, and the editors called its survival curve smoother than a phase 3 trial should produce. A top journal published it anyway. The early-infusion claim is gone, but the body-clock question is still open.
CancerKetamine Failed Its Only Adequately Powered Cancer-Pain Trial, and Palliative Care Still Reaches for It
Ketamine's one adequately powered trial in advanced cancer pain found no benefit over placebo, more toxicity and worse quality of life. Fourteen years on, a 2026 review still tells clinicians to consider it.
Autoimmune & InflammationNovartis Halted Eight Autoimmune CAR-T Trials After Three Deaths, Then Called the Killer a "Known Risk"
Three people in Novartis's rap-cel trials died after a runaway inflammatory syndrome, and Bristol Myers froze enrollment in its rival product. Faster manufacturing is the leading suspect, and no public report yet says how many patients got the drug.
CancerMerck and Moderna Say Their Melanoma Vaccine Worked, but Two Months On the Public Still Hasn't Seen by How Much
Merck and Moderna have announced only that their phase 3 met its endpoints. The smaller trial behind the excitement missed the conventional two-sided significance bar, and one bank has modeled a price as high as $475,000 per patient.
Drugs & FDAGenSight's Blindness Gene Therapy Reached the NEJM on the Same Day It Reported €0.7 Million in Cash
Seven of ten patients blinded by retinitis pigmentosa sensed more light through special goggles after one gene injection, in an uncontrolled trial whose sponsor held €0.7 million on September 30 and warned it may not survive the year.
Autoimmune & InflammationKnee Pain Fell From 7 to 3 After This Artery Procedure, but It Keeps Struggling to Beat a Fake One
Berlin doctors plugged inflamed knee vessels with gelatin beads built to dissolve within hours, and median pain fell from 7 to 3 over a year. Nobody got a sham, and the Rotterdam trial that used one calls the effect mainly placebo.
Drugs & FDAA Heart-Failure Implant Won by 40 Points on a Questionnaire Filled Out by Patients Who Knew Which Arm They Were In
Patients given Berlin Heals' microcurrent implant reported quality-of-life gains eight times the control arm's in an open-label trial. The blood marker and exercise test that could have backed them up showed no significant difference, and the company paid for the study.
Metabolic & WeightThe 'Self-Destruct' Fat Shot Billed as Obesity Medicine Faces Its Pivotal Trial Below the Obesity Line
Caliway's CBL-514 shrank belly fat in small trials and drew obesity headlines at EASD, but its phase 3 caps enrollment below a BMI of 30 and grades flatter stomachs, not weight.
Drugs & FDATerence Tao Fears a Cancer Cure Nobody Can Explain. The FDA Clears Cancer Drugs That Never Proved They Extend Life.
Terence Tao says he would want a human expert to understand an AI cancer cure before taking it. The oncologist Vinay Prasad says that misses how medicine already works, and the receipts show the cancer drugs worth fearing are the legible ones approved on a shrinking tumor that never proved they help
InvestigationsIn Pfizer's Pivotal Trial, a Volunteer's Pericarditis Became a 'Suspected COVID' Case That Counted Against No One
The only Argentine site in Pfizer's pivotal trial was run by the same doctor who authored the results, and when a 35-year-old developed pericarditis after his second dose, the records moved the episode off the vaccine's ledger.
Drugs & FDAGaming a Cancer Trial Is 'Cheap and Easy,' Says a Former Top FDA Official
Vinay Prasad says nobody needs AI to fake a phase 3 cancer win, and a Mayo Clinic audit found 16 of 96 FDA cancer approvals rested on control arms its authors judged suboptimal.
CancerThe 80.5 Percent Headline, and the Three Confirmed Responses Behind It
Vividion led its colorectal announcement with an 80.5 percent disease-control rate. In that same group, three tumors shrank enough to count as a response.
Autoimmune & InflammationA Lupus Drug 'Failed' Its Trial. Its Patients Got Better Anyway.
Enpatoran missed its primary endpoint in 354 lupus patients. But disease activity dropped, the interferon signature fell, and the rashes cleared. The trial's model was built to catch a climbing dose-response, and the drug's effect had plateaued.
Drugs & FDAThe FDA's New Fast Lane for Experimental Drugs Is Run by a Lawyer Who Defended the Food and Tobacco Industries
Operation TrialBlazer lets drug sponsors feed their first-in-human safety data to the FDA in pieces, on a rolling clock, to shave months off the wait. The review it speeds is the one that decides whether an untested drug can go into a person at all.
CancerThe Mesothelioma Drug in This Month's Headlines Was Tested in Fifteen People
The scientist whose lab found the drug's target is also chief science officer of the company selling it, a conflict the breakthrough headlines tuck into a job title.
Drugs & FDAThe FDA's New Pilot Lets a Drug Sponsor Choose the Institution Helping Build Its First-in-Human Application, and Reviews the Pieces as They Arrive
The agency will select 8 to 10 sponsor-QRI pairs to co-develop first-in-human trial applications it reviews on a rolling basis, and its stated reason is that China and Australia get there faster.
CancerMD Anderson Made the Case for Radiation Cleanup After Immunotherapy. Then Its Own Trial Undercut It.
In the oligometastatic subgroup the strategy was built for, small and underpowered, the patients who added radiation trended the wrong way: median survival of 42 months against 75.8 for the drugs alone.
CancerSummit's $500 Million Lung Drug Split the Curve Patients Can't Feel
Ivonescimab delayed tumor progression by 2.4 months in EGFR-mutated lung cancer, but its overall-survival curve never cleared statistical significance and serious treatment-related adverse events nearly doubled.
CancerTwenty People, No Control Arm, and a Startup on the Side: Reading the Pancreatic Cancer Vaccine's Fine Print
Ninety percent of twenty volunteers made KRAS-specific T cells. None was shown to avoid cancer. Two of the investigators co-founded the company that licensed the shot from Johns Hopkins, which stands to collect royalties.
Drugs & FDAChina Runs More Drug Trials Than America. The FDA Says It Can No Longer Trust Data From Sites It Can't Inspect.
China went from under 8 percent of the world's drug trials in 2010 to passing the United States by 2020. After three deaths in Chinese studies surfaced late, the FDA says it has sometimes been denied access to the very sites whose data underpins American approvals.
CancerThe Cancer Trials That Buried Vitamin C Never Put It in a Vein
Mayo's famous trials gave advanced cancer patients vitamin C by mouth and found nothing. A randomized trial that delivered it by IV, at a dose pills cannot reach, doubled survival in metastatic pancreatic cancer.
InvestigationsBuilt to Find Nothing: Merck Tested Gardasil's Safety Against Its Own Aluminum Adjuvant
In ten of eleven pivotal trials, Merck's Gardasil 'placebo' was 225 micrograms of the same aluminum adjuvant that is in the vaccine, and serious harms counted only inside a 14-day window.
CancerA Week Instead of a Month: The Faster Prostate Radiation Was Only "As Safe" on the Coarser Ruler
PACE-C put five-fraction radiation against the four-week course in 1,208 men. On the old grading scale they matched. On the finer one the short course logged 17 percent bowel toxicity against 10 percent, and the trial still can't say whether the shorter beam controls cancer as well.